Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Angina Pectoris Drugs Market Heading Into 2029?

Over recent years, the market size for angina pectoris medication has shown consistent growth. It’s projected to expand from $12.32 billion in 2024 to $12.88 billion in 2025, with a compound annual growth rate (CAGR) of 4.5%. This growth during the historic period can be credited to the widespread occurrence of cardiovascular diseases, an aging population, lifestyle factors, a rise in hypertension rates, and the prevalence of diabetes.

The market for angina pectoris drugs is forecasted to witness significant expansion in the forthcoming years, with a projection to reach a market size of $16.42 billion by 2029, growing at an impressive compound annual growth rate (CAGR) of 6.3%. Factors driving this growth include an escalation in worldwide obesity figures, groundbreaking advancements in precision medicine, an emphasis on preventive cardiology, initiatives aimed at educating patients, and investigations into new therapeutic targets. Upcoming market trends include the use of telemedicine for distant monitoring, studies on real-world evidence and outcomes, patient-focused medication learning, strategic collaborations to enhance market reach, regulatory progress, and rapid approvals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Which Factors Are Pushing The Angina Pectoris Drugs Market Forward?

The rise in the number of cardiovascular disease cases is likely to fuel the expansion of the angina pectoris drug market. Cardiovascular diseases comprise various disorders that affect the heart and blood vessels, such as coronary artery disease, hypertension, heart failure, and stroke. The escalating frequency of cardiovascular diseases is due to multiple factors like an aging populace, unhealthy lifestyles, and the obesity crisis. Angina pectoris treatments, including nitrates, beta-blockers, and calcium channel blockers, effectively alleviate chest discomfort and pain triggered by inadequate blood supply to the heart, thereby improving patients’ overall quality of life. For example, in September 2024, data released by the British Heart Foundation, a cardiovascular research charity based in the UK, approximated that about 7.6 million people in the UK are affected by heart and circulatory diseases. Around 4 million men and 3.6 million women are living with these conditions. These diseases account for approximately 27% of all deaths in the UK, or over 170,000 deaths per year, approximate to 480 deaths per day, or one death every three minutes. As such, the rising frequency of cardiovascular diseases is propelling the growth of the angina pectoris drug market.

Which Segment Held The Largest Share In The Angina Pectoris Drugs Market In 2025?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

How Are Key Trends Driving Expansion In The Angina Pectoris Drugs Industry?

The angina pectoris drugs market is experiencing a significant trend in product innovation. Market-leading companies are increasingly utilizing new technologies to maintain their market standing. For example, Hikma Pharmaceuticals PLC, a pharmaceutical company from the UK, introduced the Labetalol Hydrochloride Injection, USP, in a prefilled syringe in March 2023. This product has received authorization from the United States’ Food and Drug Administration. Within hospital settings, the 10 mg/2 mL PFS version of this product is employed to treat extreme hypertension and reduce blood pressure.

Which Organizations Are Driving Progress In The Angina Pectoris Drugs Industry?

Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Angina Pectoris Drugs Industry?

North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model